insights_auto
NOVOB80 niyə bu qədər qalxıb: 2,33%?
Ətraflı araşdırınchevron_right
NOVOB80:BKK
NOVOB80 KTB DR
1,32 ฿
arrow_upward
+2,33%(+0,030) 1D
16 okt, 02:55:30 GMT+7 · THB
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoNOVOB80 üçün ən vacib statistik məlumatlar yaradılır...
Açın
1,28 ฿
Yüksək
1,30 ฿
Aşağı
1,27 ฿
Bazar kapitalizasiyası
133,83 mlrd
Ortalama həcm
3,88 mln
Həcm
4,35 mln
52 həftəlik ən yüksək
2,02 ฿
52 həftəlik ən aşağı
1,12 ฿
Dövriyyədəki səhmlər
3,00 mlrd
İşçilərin sayı
67K
Açın
1,28 ฿
Yüksək
1,30 ฿
Aşağı
1,27 ฿
Bazar kapitalizasiyası
133,83 mlrd
Ortalama həcm
3,88 mln
Həcm
4,35 mln
52 həftəlik ən yüksək
2,02 ฿
52 həftəlik ən aşağı
1,12 ฿
Dövriyyədəki səhmlər
3,00 mlrd
İşçilərin sayı
67K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
Foreign Policy Journal
·
5 saat öncə
Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount
TradingKey
·
13 saat öncə
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Traders Union
·
17 saat öncə
Why is Novo Nordisk stock up 3.2% today?
Traders Union
·
23 saat öncə
Novo Nordisk stock consolidates amid seller pressure near $38.39 resistance
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
NOVOB80 KTB DR haqqında
Baş İcraçı DirektorMaziar Mike Doustdar
İşçilər66,7K
Təsis Tarixi1923
Baş OfisBagsværd, Capital Region of Denmark, Danimarka
SektorPharmaceutical industry
Veb-saytnovonordisk.com